Advanced oxidation protein products promote NADPH oxidase-dependent β-cell destruction and dysfunction through the Bcl-2/Bax apoptotic pathway
Authors:
Open Access
- 1 July 2017
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 97 (7) , 792-805
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Advanced Oxidation Protein Products Activate Intrarenal Renin–Angiotensin System via a CD36-Mediated, Redox-Dependent PathwayAntioxidants & Redox Signaling, 2013
- The renin–angiotensin–aldosterone system and glucose homeostasisTrends in Pharmacological Sciences, 2011
- Eicosanoids, β-cell function, and diabetesProstaglandins & Other Lipid Mediators, 2011
- Angiotensin I–Converting Enzyme Type 2 (ACE2) Gene Therapy Improves Glycemic Control in Diabetic MiceDiabetes, 2010
- High glucose inhibits glucose‐6‐phosphate dehydrogenase, leading to increased oxidative stress and β‐cell apoptosisThe FASEB Journal, 2009
- Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanismsKidney International, 2009
- Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidaseAmerican Journal of Physiology-Renal Physiology, 2009
- CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein productsAmerican Journal of Physiology-Renal Physiology, 2008
- Diabetes associated cell stress and dysfunction: role of mitochondrial and non‐mitochondrial ROS production and activityThe Journal of Physiology, 2007
- Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney diseaseKidney International, 2004